ASCO 2019: Front-line pembrolizumab is promising alternative to chemotherapy for advanced gastroesophageal junction and gastric cancers
The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients…
Browsing: gastroesophageal junction